<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>周二，BioStar Capital 宣布，医疗技术公司 Amplitude Vascular Systems, Inc.已被 Stryker Corporation（SYK）以高达 8.35 亿美元的价格收购。</p>
<p>Amplitude Vascular Systems 开发了一种下一代液压血管内碎石平台，用于治疗钙化的外周动脉疾病，在获得 FDA 批准之前就进行了退出。</p>
<p>Stryker 表示，此次收购标志着其扩展血管治疗业务的重要一步。此外，它计划扩展 Pulse 系统，这是一种新的治疗选择，可能比当前使用电气气球或激光的方法更有效，以帮助更多患者。</p>
<p>在盘前交易时，SYK 的交易价格为 313.76 美元，较纽约证券交易所上涨 0.17%。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

史赛克

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>史赛克公司已收购 Amplitude Vascular Systems，交易金额最高可达 8.35 亿美元，以增强其血管治疗业务。Amplitude 开发了一种用于治疗钙化外周动脉疾病的液压血管内碎石平台。这项收购被视为史赛克扩展产品线的战略举措，包括 Pulse 系统，这可能提供更好的治疗选择。史赛克的股票目前交易价格为 313.76 美元，上涨 0.17%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Tuesday, BioStar Capital announced that Amplitude Vascular Systems, Inc., a medical technology company, has been acquired by Stryker Corporation (SYK) at a purchase price of up to $835 million.</p>
<div class="lb-trans"><p>周二，BioStar Capital 宣布，医疗技术公司 Amplitude Vascular Systems, Inc.已被 Stryker Corporation（SYK）以高达 8.35 亿美元的价格收购。</p>
</div><p>Amplitude Vascular Systems, which developed a next-generation hydraulic intravascular lithotripsy platform to treat calcified peripheral arterial disease, made the exit before getting FDA approval.</p>
<div class="lb-trans"><p>Amplitude Vascular Systems 开发了一种下一代液压血管内碎石平台，用于治疗钙化的外周动脉疾病，在获得 FDA 批准之前就进行了退出。</p>
</div><p>Stryker stated that the acquisition marked an important step in growing its vascular treatment business. Also, it plans to expand the Pulse System, a new treatment option that may work better than current methods using electric balloons or lasers, to help more patients.</p>
<div class="lb-trans"><p>Stryker 表示，此次收购标志着其扩展血管治疗业务的重要一步。此外，它计划扩展 Pulse 系统，这是一种新的治疗选择，可能比当前使用电气气球或激光的方法更有效，以帮助更多患者。</p>
</div><p>In the pre-market hours, SYK is trading at $313.76, up 0.17 percent on the New York Stock Exchange.</p>
<div class="lb-trans"><p>在盘前交易时，SYK 的交易价格为 313.76 美元，较纽约证券交易所上涨 0.17%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

史赛克以最高 8.35 亿美元收购 Amplitude Vascular Systems，以扩展其血管治疗业务